NORTHLAND

NORTHLAND

Language

The company has received special support from the National Key R&D Program—“International Science and Technology Innovation Cooperation between Governments.”

发布时间：2021-12-29

Recently, the key special project—"Joint Research on a Bio-innovative Drug for the Treatment of Dry Eye Syndrome"—under the National Key R&D Program’s “Intergovernmental International Science and Technology Innovation Cooperation” initiative, submitted by NORTHLAND, has been approved and supported by the Ministry of Science and Technology. The project is granted funding of 2.5 million yuan, with a research and development period of two years. Nie Liya, Executive Deputy General Manager of the company, serves as the project leader.

12

2021-12

The collaborative meeting for the NL003 Phase III clinical study, hosted by hospitals in Qingdao, was successfully held.

发布时间：2021-12-12

On December 11, 2021, a regional academic conference jointly organized by NORTHLAND and the Department of Vascular Surgery at Qingdao University Affiliated Hospital was held in Qingdao. The conference was themed "The Application of Gene Therapy in Lower Limb Ischemic Diseases." More than 20 experts from the fields of vascular surgery—including those from Qingdao University Affiliated Hospital, Qingdao Haici Hospital (Qingdao Traditional Chinese Medicine Hospital), and a total of nine hospitals across Qingdao city and its surrounding areas—participated in the conference. These hospitals are involved in the Phase III clinical study of our company's "Recombinant Human Hepatocyte Growth Factor Naked Plasmid Injection" (code-named NL003). The conference was chaired by Wang Haofu, Director of the Department of Vascular Surgery at Qingdao University Affiliated Hospital.

15

2021-11

Standing at a New Starting Point — Celebrating NORTHLAND’s Successful Listing on the Beijing Stock Exchange

发布时间：2021-11-15

On November 15, 2021, the Beijing Stock Exchange officially opened for trading, and NORTHLAND successfully listed on the BSE, marking another significant step forward on the company's path of pioneering innovation and continuous development, and placing it at a new starting point.

09

2021-11

Northland was successfully certificatied the ISO three-system .

发布时间：2021-11-09

Recently, our company successfully passed the audit for the three major management systems—ISO 9001 (Quality Management System), ISO 14001 (Environmental Management System), and ISO 45001 (Occupational Health and Safety Management System)—and has received the corresponding certification certificates.

25

2021-10

Construction of NORTHLAND's intelligent bioengineering drug production base officially kicks off

发布时间：2021-10-25

The intelligent bioengineering drug production base of NORTHLAND, an innovative pharmaceutical company listed on the Select Tier (stock abbreviation: NORTHLAND, stock code 430047), has officially broken ground in the Zhongguancun Tongzhou Park. This marks the official start of construction of China's first production facility for naked plasmid gene therapy drugs.

21

2021-10

The groundbreaking ceremony for NORTHLAND's intelligent bioengineering pharmaceutical production base was held.

发布时间：2021-10-21

On October 22, 2021, the groundbreaking ceremony for NORTHLAND’s intelligent bioengineering pharmaceutical production base was held in Tongzhou, Beijing. More than 100 representatives from the Beijing Federation of Overseas Chinese, the Beijing Center for Promotion of Biotechnology and New Pharmaceutical Industries, the Beijing Pharmaceutical Industry Association, Zhongguancun Development Group, CITIC Securities, and other investment and financial institutions, as well as company shareholders, business partners, and all employees of the company, attended the groundbreaking ceremony and jointly witnessed another significant milestone in the company’s development history.

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Friendly Links: Baidu | NORTHLAND

NORTHLAND

Contact Information

Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing

Hotline: +86 010-82890893

Email: northland@northland-bio.com

Website: www.northland-bio.com

Complaints Reporting Hotline: +86 010-82890893-8031

Complaints Reporting Email: pv@northland-bio.com

Follow Us

Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.

WeChat Mini Program

Web site

WeChat Official Account

NL-BIO

Scientific Research on Lower Limb Ischemia

NL003

Myocardial Infarction Scientific Research

NL005

Business license

Powered by 300.cn  Privacy Policy